2010年～現在

Fukuno S, Nagai K, Yamaoka S, Yamada F, Mizumoto H, Ito T, Konishi H. Doxorubicin alters the disposition of phenytoin by reducing its metabolic elimination and binding affinity to serum albumin in rats. J Pharm Pharmacol, 74, 200-207 (2022).
Nagai K, Ryuno Y, Iwanami Y, Omotani S, Fukuno S, Hatsuda Y, Konishi H, Myotoku M. Effects of concurrent and staggered dosing of semi-solid enteral nutrients on pharmacokinetic behavior of antiepileptic drugs after oral administration in rats. PLoS One, 16, e0259400.
Nagai K, Fukuno S, Shiota M, Tamura M, Yabumoto S, Konishi H. Differences in transport characteristics and cytotoxicity of epirubicin and doxorubicin in HepG2 and A549 Cells. Anticancer Res, 41, 6105-6112 (2021).
Nagai K, Fukuno S, Miura T, Uchino Y, Sehara N, Konishi H. Reduced cytotoxicity in doxorubicin-induced HepG2 cells pretreated with menthol due to up-regulation of p-glycoprotein. Pharmazie, 75, 510-511 (2020).
Nagai K, Fukuno S, Yamamoto K, Omotani S, Hatsuda Y, Myotoku M, Konishi H. Down-regulation of organic cation transporter 1 and breast cancer resistance protein with the induction of pregnane X receptor in rat kidney impaired by doxorubicin. Pharmazie, 74, 744-746 (2019).
Fukuno S, Nagai K, Yamamoto K, Tanimura T, Nabe T, Konishi H. Pharmacokinetic interference of doxorubicin with tolbutamide due to reduced metabolic clearance with increased serum unbound fraction in rats. Biopharm Drug Dispos, 40, 225-233 (2019).
Fukuno S, Nagai K, Fujiike M, Sasaki Y, Konishi H. Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam. Xenobiotica, 49, 1470-1477 (2019).
Nagai K, Fukuno S, Omachi A, Omotani S, Hatsuda Y, Myotoku M, Konishi H. Enhanced anti-cancer activity by menthol in HepG2 cells exposed to paclitaxel and vincristine: Possible involvement of CYP3A4 downregulation. Drug Metab Pers Ther, 34, /j/dmdi.2019.34.issue-1/dmpt-2018-0029/dmpt-2018-0029.xml. (2019).
Fukuno S, Nagai K, Horii A, Yamamoto K, Konishi H. Pharmacokinetics and metabolic elimination of tolbutamide in female rats: Comparison with male rats. Biopharm Drug Dispos, 39, 321-327 (2018).
Nagai K, Fukuno S, Otani K, Nagamine Y, Omotani S, Hatsuda Y, Myotoku M, Konishi H. Prevention of doxorubicin-Induced renal toxicity by theanine in rats. Pharmacology, 101, 219-224 (2018).
Fukuno S, Nagai K, Kasahara K, Mizobata Y, Omotani S, Hatsuda Y, Myotoku M, Konishi H. Altered tolbutamide pharmacokinetics by a decrease in hepatic expression of CYP2C6/11 in rats pretreated with 5-fluorouracil. Xenobiotica, 48, 53-59 (2018).
Fukuno S, Nagai K, Yoshida S, Suzuki H, Konishi H. Taurine as a protective agent for 5-fluorouracil-induced hepatic damage related to oxidative stress. Pharmazie, 71, 530-532 (2016).
Nagai K, Fukuno S, Suzuki H, Konishi H. Higher gene expression of CYP1A2, 2B1 and 2D2 in the brain of female compared with male rats. Pharmazie, 71, 334-336 (2016).
Nagai K, Fukuno S, Oda A, Konishi H. Protective effects of taurine on doxorubicin-induced acute hepatotoxicity through suppression of oxidative stress and apoptotic responses. Anticancer Drugs, 27, 17-23 (2016).
Nagai K, Yoshida N, Kiyama M, Kasahara K, Yamamura A, Konishi H. Decreased elimination clearance of midazolam by doxorubicin through reductions in the metabolic activity of hepatic CYP3A in rats. Xenobiotica, 45, 874-880 (2015).
Nagai K, Oda A, Konishi H. Theanine prevents doxorubicin-induced acute hepatotoxicity by reducing intrinsic apoptotic response. Food Chem Toxicol, 78, 147-152 (2015).
Nagai K, Suzuki S, Yamamura A, Konishi H. Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol. Biopharm Drug Dispos, 36, 174-182 (2015) .
Nagai K, Yoshida S, Konishi H. Gender differences in the gene expression profiles of glucose transporter GLUT class I and SGLT in mouse tissues. Pharmazie, 69, 856-859 (2014).
Konishi H, Iga I, Nagai K. Underestimation of rat serum vancomycin concentrations measured by an enzyme-multiplied immunoassay technique and the strategy for its avoidance. Drug Test Anal, 6, 350-356 (2014).
Nagai K, Konishi H. Effect of fluoxetine and pergolide on expression of nucleoside transporters and nucleic-related enzymes in mouse brain. Fundam Clin Pharmacol, 28, 217-220 (2014).
Nagai K, Nogami S, Egusa H, Konishi H. Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats. Pharmazie, 69, 125-127 (2014).
Nagai K, Inoue T, Konishi H. Increased gene expression of glucose transporters in the mouse brain after treatment with fluoxetine and pergolide. Drug Res (stuttg), 64, 389-391 (2014).
Konishi H, Morita Y, Mizumura M, Iga I, Nagai K. Difference in nephrotoxicity of vancomycin administered once daily and twice daily in rats. J Chemother, 25, 273-278 (2013).
Nagai K, Konishi H. Protection of theanine against doxorubicin-induced acute cardiac toxicity. Biomed Prev Nutr, 3, 197-199 (2013).
Nagai K, Konishi H. Expression of nucleoside transporter in the mouse testis and ovary. Am J Biochem Biotechnol, 9, 448-452 (2013).
Konishi H, Fukushima K, Sudo M, Sumi M, Minouchi T, Iga I, Shibata N, Yamaji A. Effect of blood decrease on micafungin disposition in rats. Eur J Drug Metab Pharmacokinet, 36, 35-39 (2011).
Konishi H, Fukushima K, Saotome T, Hamamoto T, Eguchi Y, Sudo M, Sumi M, Minouchi T, Iga I, Yamaji A. Impact of plasma exchange on pharmacokinetic disposition of micafungin. Ther Apher Dial, 14, 358-363 (2010).
Konishi H, Fukushima K, Sudo M, Sumi M, Minouchi T, Iga I, Shibata N, Takada K, Yamaji A. Reduced elimination clearance of micafungin in rats with cholestatic hyperbilirubinemia. Fundam Clin Pharmacol, 24, 457-463 (2010).

2019.09.01 ホームパーティー

2019.09.01 ホームパーティー